Axsome Therapeutics Earnings Call Signals Aggressive Growth

Axsome Therapeutics Inc. ((AXSM)) has held its Q1 earnings call. Read on for the main highlights of the call.

Axsome Therapeutics Inc. struck an upbeat tone on its latest earnings call, underscoring powerful revenue growth, a pivotal new approval for AUVELITY, and a rapidly advancing pipeline. Management acknowledged higher costs, steep discounts, and regulatory risks, but emphasized that commercial traction and expanding market opportunities are positioning the company for substantial long‑term value creation.

Strong Top-Line Revenue Growth

Axsome reported Q1 2026 revenue of $191.2 million, a 57% jump from a year earlier, powered by AUVELITY and SUNOSI along with initial SYMBRAVO contributions. The breadth of growth across the portfolio reinforced the narrative that Axsome is transitioning from a single‑product story into a diversified CNS commercial platform.

AUVELITY Commercial Performance

AUVELITY remained the core growth engine with Q1 net product revenue of $153.2 million, up 59% year over year and supported by more than 223,000 prescriptions, up 35%. First‑line and first‑switch use rose to 56% of demand, while the drug has now reached about 60,000 unique prescribers, backed by 78% commercial and 86% total coverage.

Regulatory Milestone — New Indication for AUVELITY

The quarter’s marquee catalyst was U.S. regulatory approval of AUVELITY for agitation associated with Alzheimer’s disease, following breakthrough therapy and priority review status. Management highlighted the indication as first‑in‑class and serving a high unmet‑need population, opening a potentially large second leg of growth beyond major depressive disorder.

Updated AUVELITY Peak Sales Outlook

On the back of strong adoption and the new Alzheimer’s agitation label, Axsome lifted AUVELITY’s peak sales potential to at least $8 billion annually. The company now envisions roughly equal contributions of around $4 billion each from major depressive disorder and the Alzheimer’s agitation market at maturity, underscoring confidence in long‑term utilization.

SUNOSI and SYMBRAVO Momentum

SUNOSI delivered Q1 net product revenue of $33.9 million, up 34% year over year, with about 54,000 prescriptions, a 16% rise despite a soft overall wake‑promoting market. SYMBRAVO, still early in its launch, generated around 17,000 prescriptions in the quarter and posted 36% growth versus Q4 2025, though revenue remains modest.

Commercial Infrastructure Expansion

To support its expanding portfolio, Axsome significantly scaled its commercial footprint, growing the AUVELITY sales force to roughly 630 representatives targeting about 68,000 health care providers. SYMBRAVO’s dedicated team has expanded to around 150 reps, while AUVELITY added 5,500 new prescribers in the quarter, bolstering readiness for the newly approved indication.

Market Access Wins

The company reported meaningful access gains, notably for SYMBRAVO, which secured a major commercial payer contract covering about 17 million lives, pushing coverage to roughly 57%. SUNOSI’s coverage remained solid at about 83% of lives, and AUVELITY now has full Medicare and Medicaid coverage, enhancing patient access across public channels.

Pipeline Progress and Business Development

Beyond marketed assets, Axsome advanced a six‑candidate, ten‑indication pipeline, including an NDA filing for AXS‑12 in narcolepsy with cataplexy. Multiple Phase III programs are slated to start soon, including solriamfetol studies for additional sleep‑wake indications and an AXS‑05 smoking‑cessation trial, while the acquisition of AXS‑20 adds a PDE10A asset moving toward Phase III‑enabling work this year.

Balance Sheet and Cash Runway

Axsome ended the quarter with $305 million in cash and equivalents, down modestly from $323 million at year‑end, as investment ramped in commercial and R&D activities. Management reiterated that this balance should fund operations into cash‑flow positivity under the current plan, though execution on launches and approvals will be key to preserving that runway.

Elevated Gross-to-Net Discounts

Profitability remains constrained by heavy gross‑to‑net discounts, with AUVELITY and SUNOSI both running in the low‑to‑mid‑50% range, though management expects gradual improvement. SYMBRAVO’s discounts are steeper, in the high‑70% range, sharply reducing realized revenue and likely to stay elevated in the near term while access and rebate structures mature.

Significant SG&A Increase

Selling, general and administrative expenses jumped to $185.0 million from $120.8 million a year earlier, as Axsome invested in national direct‑to‑consumer campaigns and expanded sales forces for AUVELITY and SYMBRAVO. The company framed these higher outlays as necessary upfront spending to capture the full value of its new indications and product launches.

Net Loss and Stock-Based Compensation

Despite strong top‑line growth, Axsome’s net loss widened to $64.5 million, or $1.26 per share, compared with $59.4 million, or $1.22, in Q1 2025. The result includes $23.4 million of stock‑based compensation, reflecting heavier use of equity incentives amid organizational scaling and talent retention efforts.

SYMBRAVO Near-Term Access & Revenue Limitations

SYMBRAVO’s prescription growth has not yet translated into substantial sales, with Q1 net revenue at $4.1 million due to limited coverage and very high gross‑to‑net headwinds. Management cautioned that while new payer wins should help over time, realized revenue will remain constrained in the near term as reimbursement and contracting improve incrementally.

SUNOSI Sequential Softness

SUNOSI’s year‑over‑year prescription growth contrasted with a 3% sequential decline versus Q4 2025, mirroring softness in the broader wake‑promoting agent market. Axsome pointed to a competitive and slow‑growing category, with the market up only about 1% year on year, though the company remains focused on preserving its share and exploring new indications.

Cash Position Decline and Runway Sensitivity

The modest drop in cash to $305 million highlights the sensitivity of Axsome’s runway to sustained high SG&A and R&D spending. While management maintains that current resources will last until the business turns cash‑flow positive, that assumption depends on timely approvals, continued prescription growth, and improving gross‑to‑net economics.

Clinical and Regulatory Uncertainties Remain

Investors were reminded that several late‑stage efforts still face clinical and regulatory risk, including key solriamfetol trials with ENGAGE data expected in the second half of 2026 and a shift‑work disorder readout in 2027. Outcomes on the AXS‑12 NDA and future AXS‑20 studies will also be pivotal in determining how fully Axsome can monetize its diversified CNS pipeline.

Forward-Looking Guidance and Strategic Outlook

Management’s guidance underscored confidence in sustained growth, anchored by Q1 metrics showing AUVELITY, SUNOSI, and SYMBRAVO collectively at $191.2 million in revenue and AUVELITY scripts growing 35%. The company guided to improving gross‑to‑net for AUVELITY and SUNOSI, maintained that existing cash can fund operations into cash‑flow positivity, and laid out a busy clinical calendar with multiple Phase III starts and key readouts over the next two years.

Axsome’s earnings call painted a picture of a company in aggressive build‑out mode, trading near‑term losses for long‑term commercial scale. With AUVELITY’s new label, an $8 billion peak sales target, and a maturing pipeline, the upside case remains compelling, though investors will be watching cost discipline, access improvements, and regulatory outcomes closely in the coming quarters.